Nyxoah Announces Impressive Q3 2025 Financial and Operational Performance

November 14, 2025 - 05:37

Nyxoah has reported strong financial and operational results for the third quarter of 2025, highlighting a successful launch of its innovative Genio implants in the U.S. market. The company has successfully completed its first commercial Genio implants, which have garnered widespread payer coverage, contributing to an encouraging initial revenue stream.

Based in Mont-Saint-Guibert, Belgium, Nyxoah specializes in developing advanced treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation technology. The positive reception of the Genio system marks a significant milestone for the company, as it aims to address the growing demand for effective OSA treatments.

The robust performance in Q3 reflects Nyxoah's commitment to improving patient outcomes and expanding its market presence. With the successful implementation of its commercial strategy, the company is poised for continued growth and innovation in the medical technology sector. As they move forward, Nyxoah remains focused on delivering transformative solutions for individuals suffering from sleep apnea.